HBM Holdings Limited announced a significant legal victory regarding its patent entitled "Binding Molecule" (Patent Application No. CN201210057668.0). The China National Intellectual Property Administration upheld the patent following an invalidation request by Biocytogen Pharmaceuticals. This decision affirms HBM Holdings' rights to its innovative method for producing fully human heavy chain-only antibodies using transgenic animals. The company plans to continue utilizing its patented technology to advance transformative therapies globally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.